Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Central nervous system disorders attention deficit hyperactivity disorder

Several medical, medication-induced, or substance-related causes of mania and depression have been identified (see Table 68-2 for causes of mania and Table 67-1 in Chap. 67 on depressive disorders for causes of depression). " A complete medical, psychiatric, and medication history physical examination and laboratory testing are necessary to rule out any organic causes of mania or depression. An accurate diagnosis is important because some psychiatric and neurologic disorders present with manic-like symptoms. For example, attention-deficit/hyperactivity disorder and a manic episode have similar characteristics thus individuals with bipolar disorder may be misdiagnosed and prescribed central nervous system stimulants. Use of any substance that affects the central nervous system (e.g., alcohol, antidepressants, caffeine, central nervous system stimulants, hallucinogens, or marijuana) can worsen symptoms and decrease the... [Pg.1259]

Histamine produces its pharmacological actions by three subtypes of receptors the postsynaptic Hi and H2 receptors and the presynaptic H3 receptor. The H3 receptor is mainly located in the central nervous system (CNS), where it acts as an inhibitory autoreceptor in the central histaminergic neuronal pathways [176]. A number of therapeutic applications have been proposed for selective H3 receptor antagonists, including several CNS disorders such as Alzheimer s disease. Attention Deficit Hyperactivity Disorder, Schizophrenia, or for enhancing memory or obesity control. [Pg.289]

Adderall XR (package insert). Wayne, PA, Shire US Inc, 2004 Angrist B, d Hollosy M, Sanfilipo M, et al Central nervous system stimulants as symptomatic treatments for AIDS-related neuropsychiatric impairment. J Clin Psychophamiacol 12 268—272, 1992 Arnold LE, Lindsay RL, Connors CK, et al A douhle-hlind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention-deficit hyperactivity disorder. I Am Acad Child Adolesc Psychiatry 14 542—554, 2004 Belle DJ, Ernest CS, Sauer JM, et al Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. I Clin Pharmacol 42 1219-1227, 2002... [Pg.193]

Prescription medications such as pain relievers, central nervous system (CNS) depressants (tranquilizers and sedatives), and stimulants are highly beneficial treatments for a variety of health conditions. Pain relievers enable individuals with chronic pain to lead productive lives tranquilizers can reduce anxiety and help patients with sleep disorders and stimulants help people with attention-deficit hyperactivity disorder (ADHD) focus their attention. Most people who take prescription medications use them responsibly. But when abused—that is, taken by someone other than the patient for whom the medication was prescribed or taken in a manner or dosage other than what was prescribed—prescription medications can produce serious adverse health effects, including addiction. [Pg.233]

The co-3 fatty acids have numerous important functions, especially in the brain. Accordingly, a deficiency of DHA and EPA may cause dysfunction of the central nervous system and probably also the retina, thereby resulting in impaired vision. In addition, there is a variety of neurological and psychiatric disorders that have been associated with decreased levels of especially DHA and AA, such as, for example, schizophrenia and depression [3], post-traumatic stress syndrome, autism and attention deficit hyperactivity disorder. Since no primary inherited defect of essential fatty acid interconversion has yet been described, no specific explanations for the essential fatty acid concentration changes are readily available. [Pg.218]

Amphetamines and similar central nervous system stimulants have been available for many years, but the substantial abuse liability and potential cardiovascular adverse effects have largely limited their use to the treatment of narcolepsy and attention-deficit-hyperactivity disorder. There has also been some utilization of amphetamines to combat sleepiness during military operations. [Pg.548]

Methylphenidate (MPH, Ritalin ) is a central nervous system stimulant that is used for the treatment of attention deficit disorders, with and without hyperactivity, and narcolepsy. MPH has two chiral centres and is marketed as a racemic mixture. It is known that d-threo-MP is pharmacologically more active than l-threo-MPH. The drag is rapidly metabohzed in humans to the inactive ritalinic acid. High-throughput analysis with chiral selectivity is demanded for the bioanalysis of MPH and its major metabolite. [Pg.302]

It was named Dopamine because it was a monoamine, and its synthetic precursor was 3,4-dihydroxyphenylalanine (L-DOPA). He was awarded Nobel Prize in 2000 along with Eric Kandel and Paul Greengard in Medicine for showing that dopamine is not just a precursor of noradrenaline and adrenaline, but also neurotransmitter as well. DO is a type of neurotransmitter naturally produced in by the human body. It is also a neurohormone released by the hypothalamus. It is a chemical messenger that is similar to adrenaline and affects the brain processes that control movement, emotional response, and the capacity to feel pleasure and pain. It is vital for performing balanced and controlled movements [172,173], In the extra-cellular fluid of the central nervous system, the basal DO concentration is very low (0.01-1 pM). Abnormal levels of DO have been linked with Parkinson s disease, Tourette s syndrome, Schizophrenia, attention deficit hyperactive disorder and generation of pituitary tumours [174-176],... [Pg.120]

Fetotoxicity In 202 children aged 4-10 years, who underwent assessment of central nervous system development with standard tests and who had been exposed prenatally to labetalol, methyldopa, or bed rest because of mild-to-moderate gestational hypertension, most of those who had been exposed to labetalol had attention deficit hyperactivity disorder than those who had been exposed to methyldopa or those whose mothers had taken bed rest [8 "]. [Pg.304]

Promising agent in the treatment of central nervous system (CNS) disorders, like Alzheimer s disease, attention deficit, restlessness, impulsiveness, hyperactivity... [Pg.338]

Tolylaldehyde glyceryl acetyl N/A Central nervous system stimulants, treat attention deficit hyperactivity disorder (Drugbank)... [Pg.120]

Nervous system Clonidine has been successfully used for impulsive and oppositional behavior in attention-deficit hyperactivity disorder as well as for its centrally mediated sedative action when taken late in the day. A child who took clonidine for this indication had night terrors shortly after initial therapy, insomnia during attempts at drug withdrawal, and depression when the drug was finally tapered and stopped... [Pg.424]

Norepinephrine (NE) is a major neurotransmitter in both the central and peripheral nervous system and is involved in regulation of a variety of body functions. Extracellular levels of norepinephrine can be increased by blocking its reuptake by the norepinephrine transporter (NET). Drugs that inhibit norepinephrine reuptake either selectively or in combination with serotonin or dopamine have demonstrated efficacy in the clinic for a variety of indications such as attention deficit hyperactivity disorder (ADHD), major depressive disorder (MDD), pain disorders (e.g. fibromyalgia), and vasomotor symptoms (VMS). In an effort to identify new selective NRIs, we designed a novel class of 1-(3-amino-1-phenylpropyl)indolin-2-ones. These compounds showed potency inhibiting NE reuptake when tested in the human norepinephrine transporter (hNET) inhibition assay. The compounds also showed selectivity (>100) against the human serotonin and dopamine transporters. The synthesis and properties of these novel compounds are described. [Pg.92]


See other pages where Central nervous system disorders attention deficit hyperactivity disorder is mentioned: [Pg.71]    [Pg.453]    [Pg.180]    [Pg.2307]    [Pg.1262]    [Pg.128]    [Pg.5]    [Pg.191]    [Pg.178]    [Pg.188]    [Pg.588]    [Pg.268]    [Pg.22]    [Pg.169]    [Pg.153]    [Pg.26]    [Pg.790]   
See also in sourсe #XX -- [ Pg.191 ]




SEARCH



Attention

Attention Deficit Hyperactive Disorders

Attention deficit/hyperactive

Attention-Deficit Disorder

Attention-deficit

Attention-deficit hyperactivity

Attention-deficit/hyperactivity disorder

Attentiveness

Central disorders

Central nervous system disorders

Deficit

Disordered systems

Hyperactive

Hyperactivity

Nervous disorders

© 2024 chempedia.info